{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.4","upperLimit":"96.6","value":"88.5"},{"groupId":"OG001","lowerLimit":"59.8","upperLimit":"94.8","value":"77.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"MRD < 0.01% BL1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.6","upperLimit":"72.4","value":"60.0"},{"groupId":"OG001","lowerLimit":"27.8","upperLimit":"64.7","value":"46.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"MRD >= 0.01% BL1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"93.5","value":"83.8"},{"groupId":"OG001","lowerLimit":"68.4","upperLimit":"98.2","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"MRD < 0.01% BL3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"88.0","value":"61.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"86.7","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"MRD >= 0.01% BL3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Percentage of patients who were event free at 3 years among those with isolated BM or combined BM relapse \\>= 36 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard VCR dosing (1.5 mg/m\\^2, max 2mg)","id":"OG000","title":"Regimen A"},{"description":"Intensive VCR dosing (2 mg/m\\^2, max 2.5 mg)","id":"OG001","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"The percentage of patients (pts) who were event free at 3 years among those with isolated BM or combined BM relapse \\>= 36 months. Pts with MRD \\<0.01% at the end of Block 1 (MRD \\< 0.01% BL1); MRD \\>= 0.01% at the end of Block 1 (MRD\\>= 0.01% BL1); MRD \\< 0.01% at the end of Block 3 (MRD \\< 0.01% BL3);MRD \\>=0.01% at the end of Block 3.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Event Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}